United Kingdom Prediabetes Market Size, Share By Drug Class (SGLT2 inhibitors, Diguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), andDPP-4 inhibitors), By Age Group (Adults (18-49), Children (12-18 years), and Elderly (50+)), United Kingdom Prediabetes Market Insights, Industry Trend, Forecasts to 2035.

United Kingdom Prediabetes Market Insights Forecasts to 2035

• United Kingdom Prediabetes Market Size 2024: USD 22.7 million
• United Kingdom Prediabetes Market Size 2035:  USD 81.6 million
• United Kingdom Prediabetes Market CAGR 2024: 12.33%
• United Kingdom Prediabetes Market Segments: Drug Class and Age Group

The UK prediabetes market is a representation of a mature and dynamically developing healthcare environment, which is driven by the increasing incidence of metabolic disorders, the high priority placed on early diagnosis and prevention, and the adoption of lifestyle management approaches, digital health solutions, and pharmacological therapies. The market is defined by the high level of clinical research, the growing use of GLP-1-based therapies, the organized prevention programs conducted by the NHS, the strict regulatory environment imposed by the MHRA, and cost-effectiveness challenges, among others.

NHS Diabetes Prevention Programme is a flagship UK govt initiative launched in 2015 across England, offering a free nine-month behavioural intervention for adults with prediabetes. It targets individuals with raised HbA1c or fasting glucose, supporting lifestyle change and reducing progression to type 2 diabetes, nationwide public health effort.

The UK prediabetes market offers Significant growth opportunities exist within the prediabetes sector within the UK due to demographic factors, arising obesity levels, increasing numbers of people who are sedentary and rising awareness surrounding early metabolic risk. There are also many areas where advancements such as predictive analytics, real-world data, genomics and artificial intelligence enabled risk stratification will help facilitate early diagnosis/identification of individuals at risk as well as personalized interventions. There is a renewed focus from pharmaceutical and digital health companies on prevention based solutions despite funding limitations and struggles with reimbursement within the NHS, leading to growth within this space.

Market Dynamics of the United Kingdom Prediabetes Market

The UK prediabetes market is driven by an aging population, rising obesity and lifestyle-related risk factors, strong government support for preventive healthcare, and growing investment in early-stage metabolic research. The favorable healthcare infrastructure, widespread screening programs, access to high-quality patient and real-world data, and the NHS-led diabetes prevention initiatives are accelerating the development of lifestyle, digital, and pharmacological interventions. In addition, supportive public health spending and collaboration between academia, healthcare providers, and industry are enabling the United Kingdom to emerge as a leading hub for prediabetes prevention, early diagnosis, and population-level metabolic health innovation.

The United Kingdom prediabetes market faces restraints such as strict NHS cost-containment and reimbursement pressures, limited pharmacological approvals specific to prediabetes, variability in screening and patient adherence, data integration challenges, workforce gaps in preventive care, and reliance on imported digital and therapeutic solutions, which collectively constrain market expansion despite strong long-term preventive healthcare potential.

The prediabetes market in the United Kingdom has a positive market outlook because of its strong preventive healthcare system and government health programs and the increasing demand from its aging population and growing obesity rates. The NHS diabetes prevention programs keep evolving through their digital health platform integration and real-world evidence use and AI risk prediction technology implementation which creates new growth opportunities. The United Kingdom prediabetes market benefits from genomic advancements and data science progress and precision lifestyle medicine development and collaboration between NHS and academic and industrial partners.

Market Segmentation

The United Kingdom prediabetes market share is classified into drug class and age group.

By Drug Class

The United Kingdom prediabetes market is divided by drug class into SGLT2 inhibitors, diguanide, thiazolidinediones, glucagon-like peptide-1 agonists (GLP-1), and DPP-4 inhibitors. Among these, the diguanide segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is also anticipated to grow at a remarkable CAGR during the forecast period, supported by its established clinical efficacy, affordability, and broad acceptance in prediabetes management.

By Age Group

The United Kingdom prediabetes market is divided by age group into adults (18-49), children (12-18 years), and elderly (50+). Among these, the adults (18-49) segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is driven by rising sedentary lifestyles, poor dietary habits, and obesity, which lead to a high prevalence of prediabetes in this demographic.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the United Kingdom prediabetes market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

Top Key Companies in United Kingdom Prediabetes Market

• AstraZeneca PLC
• Novo Nordisk A/S
• Aphaia Pharma
• Boston Therapeutics
• Valbiotis
• Resverlogix Corp
• Caelus Health
• SciMar
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom prediabetes market based on the below-mentioned segments:

United Kingdom Prediabetes Market, By Drug Class

• SGLT2 inhibitors
• Diguanide
• Thiazolidinediones
• Glucagon-like peptide-1 agonists (GLP-1)
• DPP-4 inhibitors

United Kingdom Prediabetes Market, By Age Group

• Adults (18-49)
• Children (12-18 years)
• Elderly (50+)